The EpiPen Debacle Coupled With Theranos And Turing: Is This Industry Broken?

The bad and ugly

As the CEO of a life science company, I have watched with concern the debacle of the Mylan MYL +0.63% price hike on the life-saving EpiPen, and with absolute contempt for the (debatably nefarious) actions of Martin Shkreli of Turing Pharma. You remember this guy, pumping his profits citing research and development costs, while patients suffered.

Couple these actions with the issues created by the problems at Theranos, and you have created a crisis of epic proportions in an industry that is working hard to help people while balancing a return for its investors.

Back to news